We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum YKL-40 Levels Measured In Antisynthetase Syndrome Patients

By LabMedica International staff writers
Posted on 10 Aug 2021
Print article
Antisynthetase Syndrome Patients with positive immunohistochemistry reaction of (A) YKL-40, (B) YKL-40 (higher magnification); (C), a specimen from a patient with antisynthetase syndrome, but without infiltrate inflammation; (D) CD68, (E) CD4, and (F) CD8 (Photo courtesy of Universidade de Sao Paulo).
Antisynthetase Syndrome Patients with positive immunohistochemistry reaction of (A) YKL-40, (B) YKL-40 (higher magnification); (C), a specimen from a patient with antisynthetase syndrome, but without infiltrate inflammation; (D) CD68, (E) CD4, and (F) CD8 (Photo courtesy of Universidade de Sao Paulo).
Antisynthetase syndrome (ASSD) is a rare systemic autoimmune myopathy characterized by muscle, joint, and pulmonary involvement, as well as by the presence of fever, “mechanic’s hands,” and Raynaud’s phenomenon.

The protein chitinase-3-like-1 (YKL-40) is a glycoprotein secreted by inflammatory cells, including macrophages and neutrophils. YKL-40 is associated with several physiological processes, such as inflammation, cell proliferation, angiogenesis, tissue fibrosis, and tissue remodeling.

Rheumatologists at the Universidade de Sao Paulo (Sao Paulo, Brazil) carried out a cross-sectional single-center study that took place from 2017 to 2019 and included 66 adult patients with ASSD followed up at the outpatient clinic. The patients’ mean age was 44.8 ± 11.8 years, and median disease duration was 1.5 (0.0–4.0) years. These patients were predominantly female (82.8%) and Caucasian (73.4%). Most patients had stable disease. Muscle involvement was defined as the presence of progressive and proximal limb muscle weakness, increased serum levels of muscle enzymes, such as creatine phosphokinase (CPK), myopathic pattern on electroneuromyography, and muscle biopsy compatible with inflammatory myopathy.

The scientists used a commercially available line blot test kit, the Myositis Profile Euroline Blot test kit, (Euroimmun, Lübeck, Germany; www.euroimmun.com) to identify anti-aminoacyl-tRNA synthetase autoantibodies (anti-Jo-1, anti-EJ, anti-OJ, anti-PL-7, anti-PL-12, and anti-Ro-52). The YKL-40 quantification was performed using a specific kit (Human CHI3L1 ELISA kit, RayBiotech, Peachtree Corners, GA, USA). The interferon gamma (IFN-γ) and TNF-α tests were performed using the LUMINEX 100/200x xMAP technology (Millipore, Burlington, MA, USA). Additionally, the YKL-40 expression and location were assessed in muscle tissues of three patients with ASSD, whose biopsies were taken from the vastus lateralis muscle upon diagnosis.

The investigators reported that the median YKL-40 serum level was significantly higher in patients with ASSD when compared to the healthy individuals: 538.4 (363.4–853.1) pg/mL versus 270.0 (201.8–451.9) pg/mL, respectively. However, YKL-40 serum levels did not correlate with any clinical, laboratory, disease status, or therapeutic parameters, except tumor necrosis factor alpha (TNF-α) serum levels. YKL-40 was highly expressed by inflammatory cells found in muscle biopsy specimens.

The authors concluded that there were high YKL-40 serum levels in patients with ASSD, and these correlated positively with TNF-α serum levels. Although other studies have shown the expression of YKL-40 in lungs of patients with various systemic autoimmune myopathies, they have shown high YKL-40 levels in inflammatory muscle tissue cells. The study was published on July 5, 2021 in the journal Advances in Rheumatology.

Related Links:

Universidade de Sao Paulo 
Euroimmun
RayBiotech 
Millipore

New
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
Dual-Channel Optical Coagulation Analyzer
Sensa2
New
Infliximab Immunoassay
RIDASCREEN IFX Monitoring
New
Anti-HIV 1/2 ELISA Test
HIV 1/2 Antibody (3rd) Test Kit (ELISA)

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.